Nanoparticle albumin-bound paclitaxel with cetuximab and carboplatin as first-line therapy for recurrent or metastatic head and neck cancer: A single-arm, multicenter, phase 2 trial.

导出 OA

翻译打印收藏纠错

作者： Douglas,Adkins ^[1] ; Jessica,Ley ^[2] ; Omar,Atiq ^[3] ; Steven,Powell ^[4] ; William C,Spanos ^[4] ; Mark,Gitau ^[5] ; Caron,Rigden ^[6] ; Kevin,Palka ^[6] ; Jingxia,Liu ^[7] ; Peter,Oppelt ^[6]

作者单位： Alvin J. Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO, United States; Division of Medical Oncology, Washington University School of Medicine, St. Louis, MO, United States. Electronic address: dadkins@wustl.edu. ^[1] Division of Medical Oncology, Washington University School of Medicine, St. Louis, MO, United States. ^[2] Winthrop P. Rockefeller Cancer Institute, University of Arkansas Medical System, Little Rock, AR, United States. ^[3] Sanford Cancer Center, Sanford Health, Sioux Falls, SD, United States. ^[4] Sanford Cancer Center, Sanford Health, Fargo, ND, United States. ^[5] Alvin J. Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO, United States; Division of Medical Oncology, Washington University School of Medicine, St. Louis, MO, United States. ^[6] Biostatistics Shared Resource, Alvin J. Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO, United States. ^[7]

关键词 Carboplatin Cetuximab Head and neck squamous-cell carcinoma Metastatic disease Nab-paclitaxel Recurrent disease